## BDX: Becton, Dickinson and Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.6% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($186.32)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. BD Stock Up Post Tie-Up to Expand Hazardous Drug Contamination Testing**
- Source: Nasdaq | 20251205T220730 | Somewhat-Bullish | Relevance: 100%
-  Becton, Dickinson and Company (BDX) has announced a collaboration with ChemoGLO to advance hazardous drug contamination testing in healthcare settings. This partnership aims to improve healthcare worker safety by combining BD HD Check System's rapid qualitative results with ChemoGLO's quantitative analysis, which is expected to strengthen BD's Medication Delivery Solutions business. Following the announcement, BD's stock saw a slight gain, with positive market sentiment anticipated given the company's history of successful deals and the projected growth in the global drug screening market.

**2. Becton, Dickinson and Company $BDX Shares Sold by Mackenzie Financial Corp**
- Source: MarketBeat | 20251204T050811 | Neutral | Relevance: 99%
-  Mackenzie Financial Corp significantly reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 72.6% in the second quarter, selling 155,257 shares and retaining 58,622 shares valued at approximately $10.10 million. Despite the institutional selling, BDX recently increased its quarterly dividend to $1.05 per share, representing an annualized yield of about 2.2%. Analysts currently maintain a consensus "Hold" rating on BDX with an average price target of $204.45.

**3. Investors Buy Large Volume of Becton, Dickinson and Company Call Options (NYSE:BDX)**
- Source: MarketBeat | 20251205T210819 | Somewhat-Bullish | Relevance: 99%
-  Investors have shown an unusually high bullish sentiment towards Becton, Dickinson and Company (NYSE:BDX), purchasing 10,953 call options in one day, a 1,295% increase in daily volume. This surge in call options comes as large institutional investors have increased their holdings, while company insiders have slightly reduced theirs. Analysts currently rate the stock as "Hold" with a target price of $204.45, and the company recently raised its quarterly dividend to $1.05.

**4. BD Launches New Cell Analyzer Configurations to Bring Cutting-Edge Capabilities to Labs of All Sizes**
- Source: Becton Dickinson | 20251204T060814 | Bullish | Relevance: 99%
-  BD (Becton, Dickinson and Company) has launched new configurations of its BD FACSDiscoverâ„¢ A8 Cell Analyzers, making advanced spectral and real-time imaging cell analysis capabilities more accessible to a wider range of laboratories. These new three- and four-laser instruments, which complement an existing five-laser model, enable scientists to analyze numerous cell characteristics and obtain spatial and morphological insights in real time. The initiative aims to support discoveries in fields like immunology and cancer immunotherapy by providing flexible technology options.

**5. Schroder Investment Management Group Has $12.84 Million Stock Position in Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20251204T120930 | Neutral | Relevance: 99%
-  Schroder Investment Management Group has decreased its stake in Becton, Dickinson and Company (NYSE:BDX) by 21.4% in the second quarter, now holding 74,520 shares valued at $12.84 million. Analysts maintain a "Hold" consensus with an average price target of $204.45, while the company recently raised its quarterly dividend to $1.05 per share. Insider selling has also been reported, with directors selling shares worth over $245,000 in the last 90 days.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $210 | $197 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 13 ($0.04M) |
| Sells | 6 ($0.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 10 / 0 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (+0.5%)
- Blackrock Inc.: 9.7% (+1.7%)
- T. Rowe Price Invest: 5.7% (+0.3%)
- State Street Corpora: 4.9% (+3.4%)
- JPMORGAN CHASE & CO: 3.7% (+132.7%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.99 indicates undervaluation relative to growth. Balance sheet: $2.7B free cash flow. Analyst sentiment positive (1 raises, avg +7%). Institutional flow bullish (10 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $54.1B |
| Beta | 0.28 |
| 52W Range | $162.29 - $251.99 |
| Short Interest | 1.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.99 |
| Forward P/E | 12.2 |
| Current P/E | 13.0 |
| YoY Growth | 6.5% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.8% over 5 days). Below STRENGTH zone by 4.6pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.56% (CS: 38) | Neutral |
| RSI_14 | 58.1 | Neutral |
| MACD Histogram | 0.16 | Bullish |
| vs SMA20 | 1.015x | Above |
| vs SMA50 | 1.031x | Above |
| vs SMA200 | 1.014x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $193.96
- **Stop Loss:** $186.32 (3.9% risk)
- **Target:** $201.60 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 65
- **Position Value:** $12,607.40
- **Portfolio %:** 12.61%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-09 (Est: $2.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.91 | $3.96 | +1.1% |
| 2025Q2 | $3.40 | $3.68 | +8.2% |
| 2025Q1 | $3.28 | $3.35 | +2.1% |
| 2024Q4 | $2.99 | $3.43 | +14.7% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*